Impact of aldehyde dehydrogenase 2 deficiency on tissue-specific mitochondrial metabolism in aging mice

As we age, our cells accumulate toxic byproducts called aldehydes, particularly inside mitochondria — the energy-producing compartments of cells. A key enzyme called ALDH2 normally neutralizes these aldehydes, but a very common genetic variant (ALDH2 E504K, carried by roughly 560 million people of East Asian descent) sharply reduces this enzyme's activity. This study used aging mice — both normal and carrying the human ALDH2 E504K mutation — to map how aldehyde metabolism and mitochondrial energy production change across the liver, heart, and brain with age. Strikingly, the liver showed a degree of resilience to aging (even boosting ALDH2 activity), but this protective adaptation was abolished in mice carrying the E504K mutation. The heart showed a mixed picture: some energy-production steps worsened while others compensated, and the mutation further eroded aldehyde detox capacity. The brain was the most vulnerable organ, showing declining ALDH2 activity, impaired mitochondrial function, and measurable deficits in cognition and behavior — all worsened by the E504K mutation or by acute alcohol exposure. The study also tested a pharmacological ALDH2 activator in aged tissues in vitro, pointing toward a potential therapeutic strategy.

• Aged mouse livers showed enhanced ALDH2 activity and improved mitochondrial coupling compared with young controls — a resilience response — but this adaptive phenotype was completely lost in ALDH2 E504K mice, revealing that the mutation specifically undermines the liver's compensatory capacity during aging.
• Aged hearts exhibited impaired mitochondrial basal respiration alongside paradoxically improved ADP-driven (state 3) respiration, suggesting partial compensation; however, ALDH2 detoxification capacity was already reduced by aging and was further exacerbated by the E504K mutation.
• The aging brain showed the most severe phenotype: decreased ALDH2 enzymatic activity, broadly impaired mitochondrial bioenergetics, and defective aldehyde detox capacity, which were accompanied by measurable cognitive and behavioral dysfunction in aged mice — deficits that were worsened by either the ALDH2 E504K genotype or an acute ethanol challenge, and that were partially rescued by pharmacolog

This is a preprint (bioRxiv, posted May 2026) reporting a multi-tissue, cross-sectional study in aging mice (young vs. aged cohorts) comparing wild-type animals with knock-in mice carrying the human ALDH2 E504K point mutation. Tissues examined include liver, heart, and brain; readouts span ALDH2 enzymatic activity, high-resolution mitochondrial respirometry (basal, ADP-driven, and uncoupled respiration), and aldehyde detoxification assays. Cognitive and behavioral function was assessed in vivo using standard behavioral paradigms, with acute ethanol challenge used as a proof-of-concept stressor. In vitro pharmacological activation of ALDH2 was tested in aged tissue preparations to evaluate therapeutic potential; specific sample sizes (n per group) and the pharmacological agent used are not detailed in the abstract.

As a mouse study, findings may not translate directly to humans, particularly given species differences in aging trajectories, mitochondrial metabolism, and basal ALDH2 expression levels. The cross-sectional design precludes causal mechanistic conclusions about the temporal sequence of aldehyde accumulation, mitochondrial decline, and organ-specific dysfunction. Specific aldehydes (4-HNE and acetaldehyde) are implicated but the relative contribution of each to the observed organ-specific phenotypes is not resolved. The next critical experiments would include longitudinal studies, human biobank validation of the E504K phenotype in aged tissues, and in vivo (rather than in vitro) testing of ALDH2-activating therapeutics across tissue types.

This study extends [§99], which examines mitochondrial dysfunction as a driver of aging and senescence via mtRNA release and inflammation, by adding a complementary aldehyde-metabolism axis through which mitochondrial stress accelerates age-related degeneration in a tissue-specific manner. It parallels [§135], which investigates heterogeneous mitochondrial gene expression responses to stress across cell contexts, reinforcing the emerging principle that mitochondrial vulnerability to metabolic insults is highly tissue- and genotype-dependent rather than uniform. The organ-specific bioenergetics profiling approach also parallels [§123], which dissects mitochondrial metabolic regulation through post-translational modification of a mitochondrial enzyme (TAMM41/cardiolipin axis), converging on the idea that enzyme-level control of mitochondrial membrane and metabolic integrity is a targetable node in disease. The cognitive and behavioral phenotyping of aging ALDH2-deficient mice creates a direct conceptual bridge to [§29] (NAD+/SIRT2 signaling in mitochondrial aging), as both studies highlight that upstream mitochondrial metabolic regulators govern downstream neurological and systemic aging outcomes. Finally, the study's focus on brain vulnerability and pharmacological rescue in aged tissue partially contextualizes findings from [§125], which identifies molecular targets improving age-related tissue dysfunction through distinct signaling pathways, collectively building a multi-pathway picture of mitochondria-centered aging biology.

• Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence
  Both study mitochondrial dysfunction in aging, but [id=99] focuses on mtRNA-driven inflammaging while this article centers on aldehyde accumulation and ALDH2 — comparing them reveals two parallel, potentially synergistic mechanisms of mitochondrial aging.
• NMN/NAD+ enhances SIRT2-modulated microtubule dynamics to improve mitochondrial and mitophagy functions in senescent cells
  Both converge on mitochondrial metabolism as a regulator of cognitive and systemic aging outcomes, but through different upstream nodes (ALDH2/aldehyde detox vs. NAD+/SIRT2 signaling), making direct mechanistic comparison instructive.
• SIRT5-dependent desuccinylation licenses UBR5-mediated degradation of TAMM41 to regulate mitochondrial metabolism in lung adenocarcinoma
  Both interrogate enzyme-level control of mitochondrial metabolic integrity across tissues, with [id=123] examining TAMM41/cardiolipin regulation and this article examining ALDH2/aldehyde detox — useful for understanding convergent mitochondrial vulnerabilities.
• Heterogeneous Mitochondrial Gene Expression in SH-SY5Y Cells Following ERRa and ERRy Depletion Reveals Divergent Stress Responses
  Both demonstrate that mitochondrial stress responses are heterogeneous across cell types and genetic contexts rather than uniform, reinforcing the tissue-specificity theme central to this article's liver-heart-brain comparison.
• Diphlorethohydroxycarmalol isolated from <i>Ishige okamurae</i> improves age-related muscle dysfunction by Ca<sup>2+</sup>-dependent response <i>via</i> the SirT1/PGC-1α pathway <i>in vitro</i> and <i>i
  Both investigate age-related tissue dysfunction and pharmacological rescue strategies targeting mitochondria-linked pathways, allowing comparison of intervention strategies and the degree to which different molecular targets overlap.